Real-world experience of venetoclax for patients with newly diagnosed acute myeloid leukemia in Japan: a Multicenter Observational Study
Not Applicable
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- JPRN-UMIN000050247
- Lead Sponsor
- AbbVie GK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients who explicitly declines the use of data for this study. 2.Patients who received prior lines of therapy for AML. (Note that patients treated with AZA for MDS will be included in this study)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome 1.Overall survival (OS)
- Secondary Outcome Measures
Name Time Method Secondary outcome: 1.Event-free survival (EFS) 2.Response rate, time to first response, duration of response (DoR) 3.Time course of blood cell counts 4.Healthcare resource utilization (transfusion, supportive care, hospitalization/outpatient visits) 5.Treatment patterns